{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:24:17Z","timestamp":1773681857713,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Eptinezumab reduced monthly migraine days more than placebo in the DELIVER study, a clinical trial with patients with difficult\u2010to\u2010treat migraine and prior preventive treatment failures. This post hoc analysis assesses the sustained response to eptinezumab at the population and patient level and evaluates the potential for response in initial non\u2010responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with chronic or episodic migraine and two to four prior preventive treatment failures were randomized to eptinezumab 100\u2009mg, 300\u2009mg or placebo every 12\u2009weeks. Primary outcomes in this post hoc analysis are the proportion of patients with \u226530%, \u226550% or\u2009\u226575% reduction in monthly migraine days (i.e., migraine responder rates [MRRs]) during weeks 1\u201312 and weeks 13\u201324 and across 4\u2010week intervals. Secondary outcomes are maintenance and shifts in MRRs from weeks 1\u201312 to weeks 13\u201324.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between weeks 1\u201312 and 13\u201324, \u226530% MRRs increased from 65.9% to 70.4% (100\u2009mg) and from 71.0% to 74.5% (300\u2009mg), versus 36.9% to 43.1% (placebo). The \u226550% and \u226575% MRRs were sustained or increased over the 24\u2010week period. The largest increase in \u226530% MRRs occurred after the second infusion with eptinezumab. The percentage of initial non\u2010responders (&lt;30% MRRs during weeks 1\u201312) who experienced response (\u226530% MRRs during weeks 13\u201324) to the second dose was 34.7% (100\u2009mg) and 30.4% (300\u2009mg) with eptinezumab versus 21.1% with placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Across MRR thresholds, most patients who responded to eptinezumab during weeks 1\u201312 maintained or improved response during weeks 13\u201324. More than one\u2010third of initial non\u2010responders became responders after their second infusion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.16131","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T14:41:36Z","timestamp":1699886496000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Responder rates with eptinezumab over 24\u2009weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the <scp>DELIVER<\/scp> randomized clinical trial"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-5804","authenticated-orcid":false,"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[{"name":"Danish Headache Center, Rigshospitalet Glostrup University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine  Bronx NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Department of Neurology Georgetown University Hospital  Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[{"name":"Department of Neurology Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences University of L'Aquila  L'Aquila Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimos D.","family":"Mitsikostas","sequence":"additional","affiliation":[{"name":"First Neurology Department, Aeginition Hospital, Medical School National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilie Laurberg","family":"Christoffersen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn","family":"Sperling","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1915327"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32160-7"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30083-2"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13534"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31606-x"},{"issue":"15","key":"e_1_2_12_9_1","article-title":"Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: results from a single\u2010attack phase 3 study, ACHIEVE II (S38.008)","volume":"92","author":"Trugman JM","year":"2019","journal-title":"Neurology"},{"key":"e_1_2_12_10_1","unstructured":"NICE Recommendations.Eptinezumab.2023. Accessed December 1 2022.https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid\u2010ta10677"},{"key":"e_1_2_12_11_1","unstructured":"NICE Recommendations.Erenumab.2021. Accessed December 1 2022.https:\/\/www.nice.org.uk\/guidance\/TA682\/chapter\/1\u2010Recommendations"},{"key":"e_1_2_12_12_1","unstructured":"NICE Recommendations.Fremanezumab.2022. Accessed December 1 2022.https:\/\/www.nice.org.uk\/guidance\/TA764\/chapter\/1\u2010Recommendations"},{"key":"e_1_2_12_13_1","unstructured":"NICE Recommendations.Galcanezumab.2020. Accessed December 1 2022.https:\/\/www.nice.org.uk\/guidance\/TA659\/chapter\/1\u2010Recommendations"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"key":"e_1_2_12_15_1","unstructured":"French National Authority for Health.Opinions on Drugs Galcanezumab (Emgality).2020. Accessed December 1 2022.https:\/\/www.has\u2010sante.fr\/jcms\/p_3191463\/en\/emgality"},{"key":"e_1_2_12_16_1","unstructured":"French National Authority for Health.Opinions on Drugs Fremanezumab (Ajovy).2022. Accessed December 1 2022.https:\/\/www.has\u2010sante.fr\/jcms\/p_3367543\/en\/ajovy\u2010fremanezumab"},{"key":"e_1_2_12_17_1","unstructured":"CADTH Common Drug Review.Erenumab (Aimovig).2020. Accessed December 1 2022.https:\/\/www.cadth.ca\/erenumab"},{"key":"e_1_2_12_18_1","unstructured":"CADTH.Reimbursement Review Fremanezumab (Ajovy).2021. Accessed December 1 2022.https:\/\/www.cadth.ca\/fremanezumab"},{"issue":"1","key":"e_1_2_12_19_1","first-page":"1","article-title":"CADTH Reimbursement Recommendation Galcanezumab (Emgality)","volume":"2","year":"2022","journal-title":"Canadian Journal of Health Technologies"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","unstructured":"CADTH.Reimbursement Review Eptinezumab (Vyepti).2022. Accessed December 1 2022.https:\/\/www.cadth.ca\/eptinezumab","DOI":"10.51731\/cjht.2023.537"},{"key":"e_1_2_12_21_1","unstructured":"ICER Calcitonin Gene\u2010Related Peptide (CGRP) Inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value final evidence report.2018. Accessed December 1 2022.https:\/\/icer.org\/wp\u2010content\/uploads\/2020\/10\/ICER_Migraine_Final_Evidence_Report_070318\u20101.pdf"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01555.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_12_25_1","unstructured":"The Danish Medicines Council's drug recommendation in the case of medicinal products for chronic migraine\u2014inclusion criteria for initiation follow\u2010up and discontinuation. Medicinradet; 1.32022."},{"key":"e_1_2_12_26_1","unstructured":"Vyepti [package insert].2022Bothell WA Lundbeck Seattle BioPharmaceuticals Inc."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02123-w"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00185-5"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14302"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01418-8"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13907"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T09:54:57Z","timestamp":1710928497000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/ene.16131"],"URL":"https:\/\/doi.org\/10.1111\/ene.16131","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"2023-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16131"}}